Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 2, 2003, Pages 184-190

  Murri, Rita ^a   Cozzi Lepri, Alessandro ^b   Phillips, Andrew N ^b   Girardi, Enrico ^c   Nasti, Guglielmo ^d   Ferrara, Sergio ^e   Mura, Maria Stella ^f   Mussini, Cristina ^g   Petrelli, Enzo ^h   Arlotti, Massimo ⁱ   De Stefano, Carlo ^j   Vigano, Paola ^k   Novati, Roberto ^l   Cargnel, Antonietta ^m   D'Arminio Monforte, Antonella ⁿ  

^a CATHOLIC UNIVERSITY   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e Hospital of Foggia   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h SAN SALVATORE HOSPITAL   (Italy)

ⁱ Rimini Hospital   (Italy)

^j Potenza   (Italy)

^k ASST Ovest Milanese   (Italy)

^l VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ NONE

more..

Author keywords

Access to care; Discontinuation; Highly active antiretroviral therapy; Survival; Toxicity; Women

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RISK; SEX DIFFERENCE; SIDE EFFECT; TREATMENT WITHDRAWAL;

EID: 0141923764     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310010-00008     Document Type: Article

References (21)

1. Centers for Disease Control. Update: AIDS, United States 2000. MMWR. 2002;51:592. Available at: http://www.cdc.gov/mmwr/PDF/wk/mm5127.pdf.
2. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352:1510-1514.
3. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001; 344:720-725.
4. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS. 1999;13:2361-2364.
5. Mocroft A, Gill MJ, Davidson W, et al. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr. 2000;24:475-482.
6. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al, for the I.Co.N.A. Study Group. Insight into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS. 2000;14:499-507.
7. Currier JS, Spino C, Grimes J, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trial Group 175 Team. J Acquir Immune Defic Syndr. 2000;24:316-324.
8. Moore J, Schuman P, Schoenbaum E, et al. Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS. 1999;13:2459-2468.
9. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med. 2000;160:365-369.
10. Moore AL, Sabin CA, Johnson MA, et al. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr. 2002;29:197-202.
11. Rezza G, Cozzi Lepri A, d'Arminio Monforte A, et al. Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group. J Acquir Immune Defic Syndr. 2000;25:56-62.
12. Moroni M. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1999;353:589-590.
13. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis. 2002;186:1086-1091.
14. Youle M, Sawyer W, for the HIV Health Economics Collaboration. Reasons for discontinuation of antiretroviral treatment: a clinical survey. AIDS. 1998;12:186.
15. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS. 2001;15:1579-1581.
16. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
17. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
18. Rabkin JG, Johnson J, Lin SH, et al. Psychopathology in male and female HIV-positive and negative injecting drug users. AIDS. 1997;11:507-515.
19. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA Study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
20. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy. Swiss HIV Cohort Study. AIDS. 1999;13:2547-2554.
21. Lewden C, Raffi F, Chene G, et al. Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy. J Acquir Immune Defic Syndr. 2001;26:480-482.